Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

Annals of Neurology

Volumn 69, Issue 1, 2011, Pages 181-192

  Villemagne, Victor L ^a,b   Pike, Kerryn E ^a,b   Chételat, Gaël ^a   Ellis, Kathryn A ^b,c   Mulligan, Rachel S ^a   Bourgeat, Pierrick ^c   Ackermann, Uwe ^a   Jones, Gareth ^a   Szoeke, Cassandra ^c   Salvado, Olivier ^c   Martins, Ralph ^d   O'Keefe, Graeme ^a   Mathis, Chester A ^e   Klunk, William E ^f   Ames, David ^g   Masters, Colin L ^b   Rowe, Christopher C ^a,b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CSIRO   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B;

AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; COGNITION; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PLAQUE, AMYLOID; POLYMORPHISM, GENETIC; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; THIAZOLES;

EID: 79551495391     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22248     Document Type: Article

References (42)

1. Masters CL, Cappai R, Barnham KJ, Villemagne VL., Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 2006; 97: 1700-1725. (Pubitemid 43873662)
2. Price JL, Morris JC., Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
3. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283: 1571-1577.
4. Parvathy S, Davies P, Haroutunian V, et al. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol 2001; 58: 2025-2032.
5. Prohovnik I, Perl DP, Davis KL, et al. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology 2006; 66: 49-55.
6. Mann DM, Marcyniuk B, Yates PO, et al. The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol Appl Neurobiol 1988; 14: 177-195.
7. Bennett DA, Cochran EJ, Saper CB, et al. Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiol Aging 1993; 14: 589-596.
8. Di Patre PL, Read SL, Cummings JL, et al. Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. Arch Neurol 1999; 56: 1254-1261.
9. Guillozet AL, Weintraub S, Mash DC, Mesulam MM., Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003; 60: 729-736.
10. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.
11. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-319.
12. Mintun MA, Larossa GN, Sheline YI, et al. [11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-452.
13. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517.
14. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-2844.
15. Martins IJ, Hone E, Foster JK, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006; 11: 721-736.
16. Ritchie K, Dupuy AM., The current status of apo E4 as a risk factor for Alzheimer's disease: an epidemiological perspective. Int J Geriatr Psychiatry 1999; 14: 695-700.
17. Villemagne VL, Fodero-Tavoletti MT, Pike KE, et al. The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. Mol Neurobiol 2008; 38: 1-15.
18. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 6820-6825.
19. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-1283.
20. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122-131.
21. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C] PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009; 73: 1186-1192.
22. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866.
23. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-1365.
24. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73: 754-760.
25. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672-687.
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
27. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
28. Ourselin S, Roche A, Subsol G, et al. Reconstructing a 3D structure from serial histological sections. Image Vision Computing 2001; 19: 25-31.
29. Collins DL, Zijdenbos AP, Kollokian V, et al. Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging 1998; 17: 463-468.
30. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289.
31. Bourgeat P, Chetelat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127.
32. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-680.
33. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9: 363-372.
34. Grimmer T, Tholen S, Yousefi BH, et al. Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Biol Psychiatry (doi: 10.1016/j.biopsych.2010.05.013).
35. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-1972.
36. Klunk WE, Mathis CA, Price JC, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2805-2807.
37. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388.
38. Mitchell AJ, Shiri-Feshki M., Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119: 252-265.
39. Busse A, Hensel A, Guhne U, et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67: 2176-2185.
40. Aisen PS, Petersen RC, Donohue MC, et al. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement 2010; 6: 239-246.
41. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65: 557-568.
42. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-1465.